Perioperative Imfinzi plus Enfortumab vedotin received U.S. FDA Priority Review for MIBC

BL-M05D1 received BTD in China for previously treated advanced Gastric/GEJ cancer

Ifinatamab deruxtecan BLA for previously treated extensive-stage SCLC was voluntarily withdrawn in the U.S.

AstraZeneca announced an equity investment and clinical collaboration with Summit Therapeutics to advance ADC combinations...

Nurix Therapeutics announced a $7 million milestone achievement under its strategic collaboration with Pfizer

Dong-A ST and Galux entered a research collaboration to develop AI-designed antibodies for ADC therapeutics